- Report
- August 2026
- 120 Pages
Global
From €4475EUR$4,750USD£3,726GBP
- Report
- August 2026
- 120 Pages
Global
From €4475EUR$4,750USD£3,726GBP
- Report
- August 2026
- 110 Pages
Global
From €4475EUR$4,750USD£3,726GBP
- Report
- August 2026
- 110 Pages
Global
From €4475EUR$4,750USD£3,726GBP
- Report
- August 2026
- 100 Pages
Global
From €4475EUR$4,750USD£3,726GBP
- Report
- August 2026
- 182 Pages
Global
From €4475EUR$4,750USD£3,726GBP
- Report
- July 2026
- 113 Pages
Global
From €4475EUR$4,750USD£3,726GBP
- Report
- July 2026
- 114 Pages
Global
From €4475EUR$4,750USD£3,726GBP
- Report
- July 2026
- 110 Pages
Global
From €4475EUR$4,750USD£3,726GBP
- Report
- July 2026
- 130 Pages
Global
From €4475EUR$4,750USD£3,726GBP
- Report
- July 2026
- 130 Pages
Global
From €4475EUR$4,750USD£3,726GBP
- Report
- July 2026
- 120 Pages
Global
From €4475EUR$4,750USD£3,726GBP
- Report
- July 2026
- 180 Pages
Global
From €4475EUR$4,750USD£3,726GBP
- Report
- July 2026
- 110 Pages
Global
From €4475EUR$4,750USD£3,726GBP
- Report
- June 2026
- 115 Pages
Global
From €4475EUR$4,750USD£3,726GBP
- Report
- May 2026
- 140 Pages
Global
From €4475EUR$4,750USD£3,726GBP
- Report
- April 2026
- 135 Pages
Global
From €4475EUR$4,750USD£3,726GBP
- Report
- May 2026
- 350 Pages
Global
From €4663EUR$4,949USD£3,882GBP
- Report
- September 2026
- 308 Pages
Global
From €2355EUR$2,500USD£1,961GBP
- Report
- September 2026
- 342 Pages
Global
From €2355EUR$2,500USD£1,961GBP

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more